Literature DB >> 20631742

Dyslipidaemia, combined oral contraceptives use and their interaction on the risk of hypertension in Chinese women.

W Wei1, Y Li, F Chen, C Chen, T Sun, Z Sun, Y Wu, J Zhou, L Ba.   

Abstract

The objective of the study was to assess the associations of dyslipidaemia, combined oral contraceptive (COC) use and their interaction on the risk of hypertension in Chinese women. In a case-control study, we evaluated 665 hypertensive women and 665 normotensive women matched on region and age in China. Hypertensive women had a higher prevalence of dyslipidaemia and higher levels of total cholesterol, triglyceride, low-density lipoprotein-cholesterol and lipoprotein a than normotensive ones (P<0.05). The risk of hypertension gradually increased with the increasing cumulative time of COC use in women (P=0.0043), especially significantly increased among those with cumulative time of COC use 15-20 and ≥20 years (adjusted odds ratio (OR)=1.46, 95% confidence interval (CI): 1.00-2.15; OR=1.49, 95% CI: 1.06-2.11), but gradually decreased from stopping use of COC (P<0.0001). The multiplicative interaction between dyslipidaemia and accumulative time of COC use ≥15 years, dyslipidaemia and family history of hypertension, or family history of hypertension and accumulative time of COC use ≥15 years was confirmed and the interaction analyses showed that they can significantly increased the risk of hypertension (adjusted OR=2.82, 95% CI: 1.59-3.27; OR=4.33, 95% CI: 3.10-6.06; OR=4.56, 95% CI: 3.07-6.77). It is concluded that dyslipidaemia, accumulative time of COC use ≥15 years and their interaction increased the risk of hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631742     DOI: 10.1038/jhh.2010.67

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  5 in total

1.  Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression.

Authors:  Lawrence A Olatunji; Young-Mi Seok; Adedoyin Igunnu; Seol-Hee Kang; In-Kyeom Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-22       Impact factor: 3.000

2.  Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis.

Authors:  Hui Liu; Jie Yao; Weijing Wang; Dongfeng Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-06-13       Impact factor: 3.738

3.  Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean women.

Authors:  Hyejin Park; Kisok Kim
Journal:  BMC Womens Health       Date:  2013-10-21       Impact factor: 2.809

4.  Dyslipidaemias in women using hormonal contraceptives: a cross sectional study in Mulago Hospital Family Planning Clinic, Kampala, Uganda.

Authors:  Ritah Bakesiima; Pauline Byakika-Kibwika; James K Tumwine; Joan N Kalyango; Gloria Nabaasa; Irene Najjingo; Grace S Nabaggala; Francis Olweny; Charles Karamagi
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

5.  The effects of the interaction between BMI and dyslipidemia on hypertension in adults.

Authors:  Na Tang; Jian Ma; Rongqin Tao; Zhijun Chen; Yide Yang; Quanyuan He; Yuan Lv; Zelong Lan; Junhua Zhou
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.